舒尼替尼阻斷STAT3通路抑制頭頸癌細胞增殖的實驗研究
發(fā)布時間：2019-05-11 06:07
【摘要】：目的:舒尼替尼是一種多靶向酪氨酸激酶抑制劑,因其可抑制與血管形成有關的多種受體酪氨酸激酶的活性,具有較好的抗血管生成作用,被應用于治療多種腫瘤。近來研究發(fā)現(xiàn),舒尼替尼能夠誘導腫瘤細胞凋亡而不依賴于其抑制血管生成作用。信號轉(zhuǎn)導及轉(zhuǎn)錄激活因子(signal transduction and activator of transcription,STAT)家族中成員STAT3作為多種酪氨酸激酶信號通路的重要組成部分,其活化后在包括頭頸癌等多種惡性腫瘤細胞中表達較高。STAT3異�；罨⒊掷m(xù)高表達與這些惡性腫瘤凋亡的抑制、腫瘤細胞增殖、腫瘤微環(huán)境血管形成及轉(zhuǎn)移關系密切。舒尼替尼能否誘導頭頸癌細胞凋亡,STAT3在此過程中是否發(fā)揮作用,目前相關報道較少。本實驗通過使用舒尼替尼分別處理UM-22B和SCC90兩種頭頸癌細胞系,觀察腫瘤細胞增殖和凋亡情況,以及STAT1和STAT3的變化,從而進一步了解舒尼替尼對頭頸癌的作用及機制,為舒尼替尼在臨床治療頭頸癌提供理論基礎。方法:體外培養(yǎng)的SCC90和UM-22B細胞,經(jīng)過不同濃度舒尼替尼處理不同時間后,分別采用MTT試驗、倒置顯微鏡觀察等方法,檢測細胞增殖抑制情況;并且采用流式細胞術檢測STAT1和STAT3磷酸化水平。結果:1舒尼替尼對兩種細胞增殖的影響:MTT顯示,舒尼替尼對SCC90細胞增殖的抑制率最高可達92.89%,24,48,72h的IC50分別是2.37、1.17和0.93μmol/L;對UM-22B細胞抑制率最高可達82.56%,24,48h的IC50分別是6.30和2.31μmol/L。用藥組不同濃度不同處理時間其生長抑制率有顯著差異,抑制率的時間-濃度依賴性明顯;2形態(tài)學變化:倒置顯微鏡下,SCC90、UM-22B細胞均顯示:對照組細胞生長較用藥組迅速,細胞貼壁生長呈“鋪路石”狀,細胞呈扁平狀多角形,胞質(zhì)飽滿,胞質(zhì)近中央部位有圓形細胞核;用藥組細胞增殖受到抑制,貼壁細胞體積變小而呈圓形,連接松解,核顏色較對照組加深;3舒尼替尼對STAT1和STAT3磷酸化水平的影響:SCC90細胞經(jīng)過0.25,0.5,1μmol/L的舒尼替尼處理2,8,16,24小時后,各實驗組中p-STAT1陽性表達與對照組相比,無統(tǒng)計學差異;而p-STAT3陽性表達與對照組相比明顯降低,并且隨著濃度增高,陽性率顯著下降,差異有統(tǒng)計學意義。UM-22B細胞經(jīng)過0.5,1,2,4μmol/L的舒尼替尼處理30分鐘和2小時后,各實驗組中p-STAT3陽性表達與對照組相比降低,并且隨著濃度增高,陽性率顯著下降。其中,兩個時間段中,0.5和1μmol/L組與對照組相比無統(tǒng)計學差異,而2和4μmol/L組有顯著性差異。結論:1舒尼替尼可以抑制頭頸鱗癌UM-22B和SCC90細胞的增殖。2舒尼替尼可以下調(diào)UM-22B和SCC90細胞STAT3磷酸化水平。3 STAT1在舒尼替尼抑制頭頸癌細胞增殖過程中磷酸化水平未見明顯升高。
[Abstract]:Aim: Schnitinib is a multi-target tyrosine kinase inhibitor. It can inhibit the activity of many receptor tyrosine kinases related to angiogenesis and has a good anti-angiogenesis effect. It has been used in the treatment of many kinds of tumors. Recently, it has been found that Schnitinib can induce apoptosis of tumor cells, independent of its inhibitory effect on angiogenesis. STAT3, a member of the signal transduction and activator of transcription (signal transduction and activator of transcription,STAT) family, is an important component of many tyrosine kinase signaling pathways. The abnormal activation and persistent high expression of STAT3 in various malignant tumor cells, including head and neck cancer, were closely related to the inhibition of apoptosis, proliferation of tumor cells and vascular formation and metastasis in tumor microenvironment. There are few reports on whether Schnitinib can induce apoptosis of head and neck cancer cells and whether STAT3 plays a role in this process. In order to further understand the effect and mechanism of Schnitinib on head and neck carcinoma, the proliferation and apoptosis of UM-22B and SCC90 cell lines, and the changes of STAT1 and STAT3 were observed by the treatment of shunitinib, respectively, in order to understand the effect and mechanism of Schnitinib on head and neck cancer. It provides a theoretical basis for the clinical treatment of head and neck cancer with sulnitinib. Methods: SCC90 and UM-22B cells cultured in vitro were treated with different concentrations of sulnitinib for different time. MTT test and inverted microscope were used to detect the inhibition of cell proliferation. The phosphorylation levels of STAT1 and STAT3 were detected by flow cytometry. Results: 1 the effect of sulnitinib on the proliferation of two kinds of SCC90 cells: MTT showed that the inhibition rate of Schnitinib on the proliferation of SCC90 cells reached 92.89%, 24,48 and 2.37 渭 mol / L, 1.17 渭 mol / L and 0.93 渭 mol / L, respectively. The highest inhibition rate of UM-22B cells was 82.56%, 24 h and 48 h IC50 were 6.30 and 2.31 渭 mol / L, respectively. In the treatment group, the growth inhibition rate was significantly different in different concentration and treatment time, and the time-concentration dependence of inhibition rate was obvious. 2 morphological changes: under inverted microscope, SCC90,UM-22B cells in the control group grew faster than those in the treatment group, the adherent growth of the cells was "paving stone", the cells were flat and polyangular, and the cytoplasm was full. Round nucleus was found near the center of cytoplasm. The proliferation of the cells in the treatment group was inhibited, the volume of the adherent cells became small and round, the junction was loosened, and the color of the nucleus was deeper than that of the control group. (3) the effect of sulnitinib on the phosphorylation of STAT1 and STAT3: there was no significant difference in the positive expression of p-STAT1 between the SCC90 cells and the control group 24 hours after treatment with 0.25 渭 mol / L, 0.51 渭 mol / L and 1 渭 mol / L sulnitinib for 2, 8, 16, 24 hours, and there was no significant difference in the positive expression of p-STAT1 between the experimental groups and the control group. The positive expression of p-STAT3 was significantly lower than that of the control group, and the positive rate decreased significantly with the increase of concentration. UM-22B cells were treated with 0.5, 1, 2, 4 渭 mol / L sulnitinib for 30 minutes and 2 hours. The positive expression of p-STAT3 in each experimental group was lower than that in the control group, and the positive rate decreased significantly with the increase of concentration. Among them, there was no significant difference between 0.5 渭 mol / L group and 1 渭 mol / L group and 4 渭 mol / L group, but there was significant difference between 2 渭 mol / L group and 4 渭 mol / L group. Conclusion: 1 Surnitinib can inhibit the proliferation of UM-22B and SCC90 cells in head and neck squamous cell carcinoma. 2 Surnitinib can down-regulate the STAT3 phosphorylation level of UM-22B and SCC90 cells. 3 STAT1 can inhibit the proliferation of head and neck cancer cells during the proliferation of head and neck cancer cells. There was no significant increase in acidizing level.
【學位授予單位】：河北醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R739.91
本文編號：2474300
[Abstract]:Aim: Schnitinib is a multi-target tyrosine kinase inhibitor. It can inhibit the activity of many receptor tyrosine kinases related to angiogenesis and has a good anti-angiogenesis effect. It has been used in the treatment of many kinds of tumors. Recently, it has been found that Schnitinib can induce apoptosis of tumor cells, independent of its inhibitory effect on angiogenesis. STAT3, a member of the signal transduction and activator of transcription (signal transduction and activator of transcription,STAT) family, is an important component of many tyrosine kinase signaling pathways. The abnormal activation and persistent high expression of STAT3 in various malignant tumor cells, including head and neck cancer, were closely related to the inhibition of apoptosis, proliferation of tumor cells and vascular formation and metastasis in tumor microenvironment. There are few reports on whether Schnitinib can induce apoptosis of head and neck cancer cells and whether STAT3 plays a role in this process. In order to further understand the effect and mechanism of Schnitinib on head and neck carcinoma, the proliferation and apoptosis of UM-22B and SCC90 cell lines, and the changes of STAT1 and STAT3 were observed by the treatment of shunitinib, respectively, in order to understand the effect and mechanism of Schnitinib on head and neck cancer. It provides a theoretical basis for the clinical treatment of head and neck cancer with sulnitinib. Methods: SCC90 and UM-22B cells cultured in vitro were treated with different concentrations of sulnitinib for different time. MTT test and inverted microscope were used to detect the inhibition of cell proliferation. The phosphorylation levels of STAT1 and STAT3 were detected by flow cytometry. Results: 1 the effect of sulnitinib on the proliferation of two kinds of SCC90 cells: MTT showed that the inhibition rate of Schnitinib on the proliferation of SCC90 cells reached 92.89%, 24,48 and 2.37 渭 mol / L, 1.17 渭 mol / L and 0.93 渭 mol / L, respectively. The highest inhibition rate of UM-22B cells was 82.56%, 24 h and 48 h IC50 were 6.30 and 2.31 渭 mol / L, respectively. In the treatment group, the growth inhibition rate was significantly different in different concentration and treatment time, and the time-concentration dependence of inhibition rate was obvious. 2 morphological changes: under inverted microscope, SCC90,UM-22B cells in the control group grew faster than those in the treatment group, the adherent growth of the cells was "paving stone", the cells were flat and polyangular, and the cytoplasm was full. Round nucleus was found near the center of cytoplasm. The proliferation of the cells in the treatment group was inhibited, the volume of the adherent cells became small and round, the junction was loosened, and the color of the nucleus was deeper than that of the control group. (3) the effect of sulnitinib on the phosphorylation of STAT1 and STAT3: there was no significant difference in the positive expression of p-STAT1 between the SCC90 cells and the control group 24 hours after treatment with 0.25 渭 mol / L, 0.51 渭 mol / L and 1 渭 mol / L sulnitinib for 2, 8, 16, 24 hours, and there was no significant difference in the positive expression of p-STAT1 between the experimental groups and the control group. The positive expression of p-STAT3 was significantly lower than that of the control group, and the positive rate decreased significantly with the increase of concentration. UM-22B cells were treated with 0.5, 1, 2, 4 渭 mol / L sulnitinib for 30 minutes and 2 hours. The positive expression of p-STAT3 in each experimental group was lower than that in the control group, and the positive rate decreased significantly with the increase of concentration. Among them, there was no significant difference between 0.5 渭 mol / L group and 1 渭 mol / L group and 4 渭 mol / L group, but there was significant difference between 2 渭 mol / L group and 4 渭 mol / L group. Conclusion: 1 Surnitinib can inhibit the proliferation of UM-22B and SCC90 cells in head and neck squamous cell carcinoma. 2 Surnitinib can down-regulate the STAT3 phosphorylation level of UM-22B and SCC90 cells. 3 STAT1 can inhibit the proliferation of head and neck cancer cells during the proliferation of head and neck cancer cells. There was no significant increase in acidizing level.
【學位授予單位】：河北醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R739.91
【參考文獻】
相關期刊論文 前6條
1 Man-Hsin Hung;Wei-Tien Tai;Chung-Wai Shiau;Kuen-Feng Chen;;Downregulation of signal transducer and activator of transcription 3 by sorafenib:A novel mechanism for hepatocellular carcinoma therapy[J];World Journal of Gastroenterology;2014年41期
2 Qian-Rong Qi;Zeng-Ming Yang;;Regulation and function of signal transducer and activator of transcription 3[J];World Journal of Biological Chemistry;2014年02期
3 賈志宇;趙云轉(zhuǎn);王維麗;張英懷;Chweeming Lim;Robert L Ferris;;萊菔硫烷對頭頸癌細胞系PCI-13中信號轉(zhuǎn)導和轉(zhuǎn)錄激活因子1和3的影響[J];實用口腔醫(yī)學雜志;2013年06期
4 賈志宇;趙云轉(zhuǎn);屈鵬飛;張英懷;Lim Chweeming;Robert L Ferris;;舒尼替尼阻斷STAT3通路抑制頭頸鱗癌細胞PCI-13增殖[J];第三軍醫(yī)大學學報;2014年01期
5 吳民華;陳小毅;蔡康榮;;JAK激酶抑制劑AG490對鼻咽癌CNE-2Z細胞增殖和凋亡的影響[J];癌癥;2009年01期
6 王俊閣;李曉明;陳英會;路秀英;;信號轉(zhuǎn)導和轉(zhuǎn)錄激活因子3在喉癌組織中的表達及臨床意義[J];臨床耳鼻咽喉頭頸外科雜志;2007年03期
，本文編號：2474300
本文鏈接：http://www.sikaile.net/yixuelunwen/zlx/2474300.html
最近更新
教材專著
